Omvoh
(Mirikizumab)ApprovedMonoclonal antibody
Eli LillyOmvoh is a monoclonal antibody that works as a Il-23p19 Inhibitor.[2] It is being used across 10 indications, with its most advanced program in Approved.[1]
Omvoh is one of 198 monoclonal antibody programs targeting Crohn's Disease. It is currently in Approved.
10
Indications
45
Total Trials
23
Active Trials
197
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
104 competitors in Ulcerative Colitis
#DrugCompanyPhaseTrials
1Omvoh
Eli LillyApproved
Humira
NovartisPhase 3
Stelara
Johnson & JohnsonPhase 3
Velsipity
PfizerPhase 3
Skyrizi
AbbViePhase 3
Jyseleca
GileadPhase 3
Tremfya
Johnson & JohnsonPhase 3
Mounjaro
Eli LillyPhase 3
Mesalazine
FerringPhase 3
Zasocitinib
TakedaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ulcerative Colitis14 trials
Show 11 more trials
ART9 trials
Show 6 more trials
Crohn's Disease8 trials
Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease
Not yet recruiting·GGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives·Phase 4·NCT07292012·110 enrolled
Show 5 more trials
Psoriasis5 trials
7 more indications
Inflammatory Conditions1 trial
Effectiveness1 trial
Lactation1 trial
Colitis, Ulcerative1 trial
Ulcerative Colitis (UC)1 trial
Chrohn's Disease1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Oct 26, 2023
OMVOH
BLA BLA761279
Oct 26, 2023
OMVOH
NDA BLA761279
Jan 15, 2025
OMVOH
NDA BLA761279
Jan 15, 2025
OMVOH
NDA BLA761279
Oct 23, 2025
OMVOH
NDA BLA761279
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mirikizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]